VEXAS Syndrome and Thrombosis: Findings of Inflammation, Hypercoagulability, and Endothelial Dysfunction
Bingwen E. Fan,Christina L.L. Sum,Bernard P.L. Leung,Mui K. Ang,Xin R. Lim,Samuel S.M. Lee,Li W. Koh,Liuh L. Goh,Wee L. Chan,Liang D. Wang,Siu L. Wong,Sen H. Tay
DOI: https://doi.org/10.1055/s-0043-1778105
2024-01-07
Seminars in Thrombosis and Hemostasis
Abstract:VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a novel autoinflammatory syndrome due to a ubiquitin like modifier activating enzyme 1 (UBA1) somatic mutation, recently discovered in 2020.[1] This mutation affects the major E1 enzyme that initiates ubiquitin conjugation of cellular proteins meant for degradation by proteasomes, where decreased ubiquitination causes accumulation of prominent intracellular vacuoles seen in myeloid and erythroid precursors in the bone marrow.[2] This autoinflammatory disease has a significant hematologic malignancy and thrombotic burden, with an increased incidence of venous thromboembolism (VTE) (36.4%), where deep vein thrombosis (DVT) is more common than pulmonary embolism (PE), with a lower incidence of arterial thrombosis (1.6%).[3] However, limited information is available on the potential mechanisms of thrombosis in patients with VEXAS syndrome. We describe two male patients with VEXAS syndrome diagnosed in Singapore and performed biomarkers evaluating the hemostatic, inflammatory, and endothelial function. Patient 1 is a 69-year-old Chinese male with a past medical history of hyperlipidemia, hypothyroidism, fatty liver, and stage 3A chronic kidney disease who presented in July 2019[3] with prolonged fever, urticarial eruption, painful cervical lymphadenitis, migratory arthralgia, myalgia, macrocytic anemia, and raised C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). He was treated with methotrexate 12.5 mg/wk and a tapering course of prednisolone from 0.5 mg/kg/d. He subsequently developed relapsing polychondritis and had recurrent flares of urticaria and painful lymphadenopathy, diagnosed on excision biopsy to be suggestive of Kikuchi's disease. In September 2020, he presented with acute right lower limb swelling with extensive DVT from the right common femoral vein to the popliteal vein seen on Doppler ultrasound. Computer tomography scans performed to exclude malignancy showed concurrent bilateral PE. His blood investigations showed worsening macrocytic anemia, mild thrombocytopenia, and persistently raised CRP and ESR. Antiphospholipid antibodies (anti-cardiolipin IgG and IgM, anti-β2-glycoprotein I, lupus anticoagulant) were negative. Antithrombin and homocysteine levels were normal. The acute thrombosis likely resulted in a mildly depressed protein C activity at 65% (reference range: 70–150%) and protein S activity at 53% (reference range: 65–130%). Given the history of prolonged fevers, rash, relapsing polychondritis, polyarthritis, and cytopenias, Sanger sequencing of peripheral blood and buccal swab samples was performed to confirm the clinical suspicion of VEXAS syndrome. This revealed a somatic mutation of UBA1 variant p.Met41leu (C121A- > C), confirming the diagnosis of VEXAS syndrome. A retrospective review of his bone marrow examination performed 1 year ago also revealed characteristic vacuolation in the myeloid series. Hydroxychloroquine 200 mg/d was added to his treatment regime of methotrexate and prednisolone. Anticoagulation of his VTE initially was with enoxaparin 1 mg/kg twice daily subcutaneously and later switched to apixaban 5 mg twice daily. His right lower limb swelling resolved clinically without any evidence of postthrombotic syndrome. After 6 months of therapeutic anticoagulation, the apixaban dose was reduced to 2.5 mg twice daily without any further thrombotic sequelae. Patient 2 is a 63-year-old Chinese male with a past medical history of provoked distal lower limb DVT with previous anticoagulation, gout, benign prostatic hyperplasia, and erosive gastritis. He presented in 2018 with fever, loss of weight, rashes with medium vessel vasculitis and panniculitis seen on skin biopsy, lymphadenopathy, macrocytic anemia, and pulmonary infiltrates with organizing pneumonia seen on lung biopsy. Inflammatory markers interleukin (IL)-1 receptor antagonist, interferon γ-induced protein 10 (IP-10), macrophage inflammatory protein-1α, IL-6, interferon-γ (IFN-γ), and monocyte chemoattractant protein-1 were elevated on a 27-plex Luminex assay after starting prednisolone and azathioprine as a steroid-sparer. IP10 was markedly elevated at 34,539 pg/mL (reference range: 0–954 pg/mL). Autoimmune antibody screen showed the presence of antinuclear antibody (1:320, mixed homogenous and nucleolar pattern) and a single positive lupus anticoagulant. Repeat lupus anticoagulant and antiphospholipid antibodies were negative. A somatic mutation of UBA1 variant p.Met41Thr was detected, confirming the diagnosis of VEXAS syndrome. The patient required high doses of prednisolone of at least 55 mg daily and failed the following steroid sparers: (1) anakinra (large local reaction), (2) azathioprine (due to worsening anemia), (3) methotrexate (stopped due to concerns of methotrexate pneumonitis), (4) tocilizumab (stopped due to paradoxical reaction with cervical lymphadenopat -Abstract Truncated-
peripheral vascular disease,hematology